2026-03-26 12:01:29
Lucid Diagnostics Reports Q4 and Full Year 2025 Financial Results with $1.5M Revenue
Expected Stock impact: Slightly Positive
Lucid Diagnostics Inc. (Nasdaq: LUCD) has announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported revenues of $1.5 million for the fourth quarter, driven by the processing of 3,664 EsoGuard tests. This marks a significant step in the company's growth trajectory, particularly as it expands its market presence through a contract with the U.S. Department of Veterans Affairs, which will enhance access to its EsoGuard test across approximately 170 VA medical centers nationwide. The contract includes Medicare-aligned pricing, which is expected to further boost revenue potential. Despite the positive revenue figures, Lucid reported an operating loss of approximately $16.3 million for the quarter, reflecting ongoing investments in growth and development. The company’s cash and cash equivalents stood at $34.7 million as of December 31, 2025, up from $22.4 million a year earlier, indicating a strengthening liquidity position. Lucid's leadership remains optimistic about converting demand into revenue in 2026, with plans to deepen relationships with the VA and expand adoption across health systems. The company also highlighted positive data from a large real-world study demonstrating the effectiveness of its EsoGuard and EsoCheck devices in detecting esophageal precancer. A conference call is scheduled for today at 8:30 AM EST to discuss these results in detail.
